Porton Biopharma is the sole manufacturer of the UK’s licensed anthrax vaccine. The vaccine is manufactured for, and on behalf of, the UK Government. It is supplied for both occupational health purposes and to protect those at risk from the use of anthrax as a biological weapon.
Porton Biopharma, is working together with Public Health England and US company Blue Willow Biologics (previously NanoBio Inc.) to develop a next generation anthrax vaccine at PBL’s facilities in Porton, Wiltshire, UK. This programme is currently funded by the US Government, through its National Institute of Allergy and Infectious Diseases (NIAID) and could be worth up to £14m ($24m) over the next few years.